ArticleExpert opinion on biological therapy2014
Epratuzumab for systemic lupus erythematosus.
Article in Expert opinion on biological therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- CD22 as a Target for Hematological Malignancies and Autoimmune Diseases.International journal of molecular sciences · 2026Review
- Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials.Experimental and therapeutic medicine · 2019Article
- [Pemphigus. Model disease for targeted therapy].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2015Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSystemic lupus erythematosus is an autoimmune multiorgan disease in which the lack of an appropriate therapy can lead to rapid organ failure and death. Immunosuppressive therapies such as corticosteroids or cyclophosphamide can slow down the disease progression but sometimes other therapies are needed. Among such therapies, epratuzumab, an antiCD22 antibody, can be potentially efficacious in this disease. AREAS COVERED: Discussion of the results from clinical studies evaluating the efficacy and safety of epratuzumab in patients with moderate or severe systemic lupus erythematosus. EXPERT OPINION: The study demonstrates that epratuzumab can improve the quality of life and can reduce the disease activity burden, but the premature termination of the studies might have limited the generation of further efficacy data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.